Cyclooxygenase-2 Inhibitor: A Potential Combination Strategy With Immunotherapy in Cancer

被引：70

作者：

Pu, Dan ^{[1
]}

Yin, Liyuan ^{[1
]}

Huang, Lin ^{[1
]}

Qin, Changlong ^{[1
]}

Zhou, Yuwen ^{[2
]}

Wu, Qiang ^{[1
]}

Li, Yan ^{[1
]}

Zhou, Qinghua ^{[1
]}

Li, Lu ^{[1
]}

机构：

[1] Sichuan Univ, West China Hosp, Dept Lung Canc Ctr, Lung Canc Ctr, Chengdu, Peoples R China

[2] Sichuan Univ, West China Hosp, Dept Oncol, Chengdu, Peoples R China

来源：

FRONTIERS IN ONCOLOGY | 2021年 / 11卷

关键词：

cyclooxygenase-2; immunotherapy; cancer; combination therapy; celecoxib; CELL LUNG-CANCER; PHASE-II TRIAL; PD-L1; EXPRESSION; PROGNOSTIC VALUE; CELECOXIB; COX-2; BIOMARKER; BLOCKADE; DRIVEN;

D O I：

10.3389/fonc.2021.637504

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The clinical application of immunotherapy is the milestone of cancer treatment. However, some patients have bad reaction. Cyclooxygenase-2 (COX-2) is frequently expressed in multiple cancer cells and is associated with poor prognosis. It is the key enzyme of prostaglandin E-2 (PGE2) that has been proved to promote the development, proliferation and metastasis of tumor cells. Recent studies further find the PGE2 in tumor microenvironment (TME) actively triggers tumor immune evasion via many ways, leading to poor response of immunotherapy. COX-2 inhibitor is suggested to restrain the immunosuppression of PGE2 and may enhance or reverse the response of immune checkpoint inhibitors (ICIs). This review provides insight into the mechanism of COX-2/PGE2 signal in immunosuppressive TME and summarizes the clinical application and trials in cancer treatment.

引用

页数：7

共 54 条

[1] EP4 Antagonism by E7046 diminishes Myeloid immunosuppression and synergizes with Treg-reducing IL-2-Diphtheria toxin fusion protein in restoring anti-tumor immunity [J].

Albu, Diana I. ;

Wang, Zichun ;

Huang, Kuan-Chun ;

Wu, Jiayi ;

Twine, Natalie ;

Leacu, Sarah ;

Ingersoll, Christy ;

Parent, Lana ;

Lee, Winnie ;

Liu, Diana ;

Wright-Michaud, Renee ;

Kumar, Namita ;

Kuznetsov, Galina ;

Chen, Qian ;

Zheng, Wanjun ;

Nomoto, Kenichi ;

Woodall-Jappe, Mary ;

Bao, Xingfeng .

ONCOIMMUNOLOGY, 2017, 6 (08)

[2] The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors [J].

不详 .

NATURE REVIEWS DRUG DISCOVERY, 2018, 17 (12) :854-+

[3] NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control [J].

Boettcher, Jan P. ;

Bonavita, Eduardo ;

Chakravarty, Probir ;

Blees, Hanna ;

Cabeza-Cabrerizo, Mar ;

Sammicheli, Stefano ;

Rogers, Neil C. ;

Sahai, Erik ;

Zelenay, Santiago ;

Reis e Sousa, Caetano .

CELL, 2018, 172 (05) :1022-+

[4] Elements of cancer immunity and the cancer-immune set point [J].

Chen, Daniel S. ;

Mellman, Ira .

NATURE, 2017, 541 (7637) :321-330

[5] COX-2 and PGE2-dependent immunomodulation in breast cancer [J].

Chen, Edward P. ;

Smyth, Emer M. .

PROSTAGLANDINS & OTHER LIPID MEDIATORS, 2011, 96 (1-4) :14-20

[6] Epidermal growth factor-induced COX-2 regulates metastasis of head and neck squamous cell carcinoma through upregulation of angiopoietin-like 4 [J].

Chiang, Kuo-Hwa ;

Shieh, Jiunn-Min ;

Shen, Chih-Jie ;

Chang, Ting-Wei ;

Wu, Pei-Ting ;

Hsu, Jinn-Yuan ;

Tsai, Jhih-Peng ;

Chang, Wen-Chang ;

Chen, Ben-Kuen .

CANCER SCIENCE, 2020, 111 (06) :2004-2015

[7] Eicosanoids in Cancer: Prostaglandin E2Receptor 4 in Cancer Therapeutics and Immunotherapy [J].

Ching, Mc Millan ;

Reader, Jocelyn ;

Fulton, Amy M. .

FRONTIERS IN PHARMACOLOGY, 2020, 11

[8] Breaking barriers for T cells by targeting the EPHA2/TGF-β/COX-2 axis in pancreatic cancer [J].

Conejo-Garcia, Jose R. .

JOURNAL OF CLINICAL INVESTIGATION, 2019, 129 (09) :3521-3523

[9] Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: A phase II trial of celecoxib and docetaxel [J].

Csiki, I ;

Morrow, JD ;

Sandler, A ;

Shyr, Y ;

Oates, J ;

Williams, MK ;

Dang, T ;

Carbone, DP ;

Johnson, DH .

CLINICAL CANCER RESEARCH, 2005, 11 (18) :6634-6640

[10] Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance) [J].

Edelman, Martin J. ;

Wang, Xiaofei ;

Hodgson, Lydia ;

Cheney, Richard T. ;

Baggstrom, Maria Q. ;

Thomas, Sachdev P. ;

Gajra, Ajeet ;

Bertino, Erin ;

Reckamp, Karen L. ;

Molina, Julian ;

Schiller, Joan H. ;

Mitchell-Richards, Kisha ;

Friedman, Paula N. ;

Ritter, Jon ;

Milne, Ginger ;

Hahn, Olwen M. ;

Stinchcombe, Thomas E. ;

Vokes, Everett E. .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (19) :2184-+

← 1 2 3 4 5 6 →